TN2014000421A1 - Methods of producing anamorelin hydrochloride having controlled chloride content - Google Patents

Methods of producing anamorelin hydrochloride having controlled chloride content

Info

Publication number: TN2014000421A1
Authority: TN; Tunisia
Prior art keywords: chloride content; methods; controlled chloride; anamorelin hydrochloride; producing
Prior art date: 2012-04-20

Application number

TN2014000421A

Other languages

English (en)

Inventor

Peter Manini

Shin-Itsu Kuwabe

Takehiko Yanagimachi

Hideyuki Yoshiyama

Groot Eleanor De

Rubio Silvina Garcia

Seemon Pines

Original Assignee

Helsinn Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-20

Filing date

2014-10-08

Publication date

2016-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000421(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-10-08 Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa

2016-03-30 Publication of TN2014000421A1 publication Critical patent/TN2014000421A1/fr

Links

108010052640 anamorelin Proteins 0.000 title abstract 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 title abstract 2
VFYAEUWJFGTGGO-GHTUPXNNSA-N 2-amino-n-[(2r)-1-[(3r)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide;hydrochloride Chemical compound Cl.C([C@@]1(C(=O)N(C)N(C)C)CN(CCC1)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 VFYAEUWJFGTGGO-GHTUPXNNSA-N 0.000 title 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
VQPFSIRUEPQQPP-MXBOTTGLSA-N anamorelin Chemical compound C([C@@]1(C(=O)N(C)N(C)C)CN(CCC1)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 VQPFSIRUEPQQPP-MXBOTTGLSA-N 0.000 abstract 2
229950005896 anamorelin Drugs 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

TN2014000421A 2012-04-20 2014-10-08 Methods of producing anamorelin hydrochloride having controlled chloride content TN2014000421A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261636108P	2012-04-20	2012-04-20
PCT/US2013/037159 WO2013158874A1 (fr)	2012-04-20	2013-04-18	Procédés de production de chlorhydrate d'anamoréline présentant une teneur en chlorure régulée

Publications (1)

Publication Number	Publication Date
TN2014000421A1 true TN2014000421A1 (en)	2016-03-30

Family

ID=48225135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2014000421A TN2014000421A1 (en)	2012-04-20	2014-10-08	Methods of producing anamorelin hydrochloride having controlled chloride content

Country Status (47)

Country	Link
US (8)	US20140018391A1 (fr)
EP (3)	EP3517532B1 (fr)
JP (3)	JP6109925B2 (fr)
KR (2)	KR102141323B1 (fr)
CN (3)	CN103857669B (fr)
AP (1)	AP2014008013A0 (fr)
AR (1)	AR090725A1 (fr)
AU (1)	AU2013249197B2 (fr)
BR (1)	BR112014025972A8 (fr)
CA (2)	CA2869893C (fr)
CL (1)	CL2014002817A1 (fr)
CO (1)	CO7131356A2 (fr)
CR (1)	CR20140530A (fr)
CY (1)	CY1120276T1 (fr)
DK (2)	DK2838892T3 (fr)
DO (1)	DOP2014000235A (fr)
EA (1)	EA031581B1 (fr)
EC (1)	ECSP14027739A (fr)
ES (2)	ES2820354T3 (fr)
GE (1)	GEP20186902B (fr)
HK (1)	HK1248694A1 (fr)
HR (1)	HRP20180316T1 (fr)
HU (2)	HUE035697T2 (fr)
IL (1)	IL235064B (fr)
JO (1)	JO3353B1 (fr)
LT (1)	LT2838892T (fr)
MA (1)	MA37524B1 (fr)
MD (1)	MD4615C1 (fr)
ME (1)	ME02966B (fr)
MX (1)	MX354793B (fr)
MY (1)	MY170068A (fr)
NI (1)	NI201400124A (fr)
NO (1)	NO2877697T3 (fr)
NZ (1)	NZ700833A (fr)
PE (1)	PE20150084A1 (fr)
PH (1)	PH12014502351A1 (fr)
PL (2)	PL3290410T3 (fr)
PT (2)	PT2838892T (fr)
RS (1)	RS56869B1 (fr)
SG (2)	SG11201406478XA (fr)
SI (2)	SI2838892T1 (fr)
TN (1)	TN2014000421A1 (fr)
TW (2)	TWI589572B (fr)
UA (1)	UA116207C2 (fr)
UY (1)	UY34753A (fr)
WO (1)	WO2013158874A1 (fr)
ZA (1)	ZA201408508B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3353B1 (ar)	2012-04-20	2019-03-13	Ono Pharmaceutical Co	شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
AP2017009772A0 (en)	2014-09-04	2017-02-28	Helsinn Healthcare Sa	Medical treatments based on anamorelin
MX2018001014A (es)	2015-07-24	2018-05-23	Newlink Genetics Corp	Sales y profarmacos de 1-metil-d-triptofano.
CN108239141A (zh) *	2016-12-23	2018-07-03	江苏先声药业有限公司	一种阿拉莫林的制备方法
CN115569120A (zh) *	2019-08-30	2023-01-06	赫尔森保健股份公司	具有改善稳定性的阿拉莫林片剂的生产方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA73530C2 (uk) *	1999-11-10	2005-08-15	Ново Нордіск А/С	Сполука з властивостями вивільнювати гормон росту
WO2005030698A1 (fr) *	2003-09-26	2005-04-07	Ranbaxy Laboratories Limited	Procede de preparation de voglibose
US7825138B2 (en)	2004-06-29	2010-11-02	Helsinn Therapeutics (U.S.), Inc.	Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
CA2677813A1 (fr)	2007-02-13	2008-08-21	Helsinn Therapeutics (U.S.), Inc.	Procede de traitement des troubles proliferatifs cellulaires utilisant un secretagogue d'hormone de croissance
UA105657C2 (uk) *	2009-02-27	2014-06-10	Хелсінн Терапьютікс (Ю.Ес.), Інк.	Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) *	2012-04-20	2019-03-13	Ono Pharmaceutical Co	شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

2013
- 2013-04-15 JO JOP/2013/0101A patent/JO3353B1/ar active
- 2013-04-17 AR ARP130101264A patent/AR090725A1/es not_active Application Discontinuation
- 2013-04-18 EP EP19155007.8A patent/EP3517532B1/fr active Active
- 2013-04-18 JP JP2015507175A patent/JP6109925B2/ja active Active
- 2013-04-18 WO PCT/US2013/037159 patent/WO2013158874A1/fr not_active Ceased
- 2013-04-18 DK DK13719344.7T patent/DK2838892T3/en active
- 2013-04-18 HU HUE13719344A patent/HUE035697T2/en unknown
- 2013-04-18 NZ NZ700833A patent/NZ700833A/en unknown
- 2013-04-18 MY MYPI2014703092A patent/MY170068A/en unknown
- 2013-04-18 SI SI201330963T patent/SI2838892T1/en unknown
- 2013-04-18 TW TW102113767A patent/TWI589572B/zh active
- 2013-04-18 LT LTEP13719344.7T patent/LT2838892T/lt unknown
- 2013-04-18 US US13/865,649 patent/US20140018391A1/en not_active Abandoned
- 2013-04-18 MA MA37524A patent/MA37524B1/fr unknown
- 2013-04-18 PT PT137193447T patent/PT2838892T/pt unknown
- 2013-04-18 AU AU2013249197A patent/AU2013249197B2/en active Active
- 2013-04-18 AP AP2014008013A patent/AP2014008013A0/xx unknown
- 2013-04-18 SG SG11201406478XA patent/SG11201406478XA/en unknown
- 2013-04-18 CN CN201380003026.5A patent/CN103857669B/zh active Active
- 2013-04-18 PL PL17192651T patent/PL3290410T3/pl unknown
- 2013-04-18 EA EA201401151A patent/EA031581B1/ru unknown
- 2013-04-18 BR BR112014025972A patent/BR112014025972A8/pt not_active Application Discontinuation
- 2013-04-18 PE PE2014001624A patent/PE20150084A1/es not_active Application Discontinuation
- 2013-04-18 CA CA2869893A patent/CA2869893C/fr active Active
- 2013-04-18 CN CN201910323606.1A patent/CN110041398A/zh active Pending
- 2013-04-18 CN CN201910323598.0A patent/CN110041304A/zh active Pending
- 2013-04-18 CA CA3031652A patent/CA3031652C/fr active Active
- 2013-04-18 EP EP17192651.2A patent/EP3290410B1/fr active Active
- 2013-04-18 RS RS20180192A patent/RS56869B1/sr unknown
- 2013-04-18 DK DK19155007.8T patent/DK3517532T3/da active
- 2013-04-18 PL PL13719344T patent/PL2838892T3/pl unknown
- 2013-04-18 ES ES17192651T patent/ES2820354T3/es active Active
- 2013-04-18 ES ES13719344.7T patent/ES2658862T3/es active Active
- 2013-04-18 TW TW106105466A patent/TWI677494B/zh active
- 2013-04-18 KR KR1020197011485A patent/KR102141323B1/ko active Active
- 2013-04-18 HR HRP20180316TT patent/HRP20180316T1/hr unknown
- 2013-04-18 MD MDA20140122A patent/MD4615C1/ro active IP Right Grant
- 2013-04-18 GE GEAP201313634A patent/GEP20186902B/en unknown
- 2013-04-18 ME MEP-2018-47A patent/ME02966B/fr unknown
- 2013-04-18 HU HUE17192651A patent/HUE050865T2/hu unknown
- 2013-04-18 PT PT191550078T patent/PT3517532T/pt unknown
- 2013-04-18 SG SG10201608488RA patent/SG10201608488RA/en unknown
- 2013-04-18 MX MX2014012178A patent/MX354793B/es active IP Right Grant
- 2013-04-18 UA UAA201412382A patent/UA116207C2/uk unknown
- 2013-04-18 KR KR1020147018116A patent/KR101972998B1/ko active Active
- 2013-04-18 EP EP13719344.7A patent/EP2838892B1/fr active Active
- 2013-04-18 SI SI201331789T patent/SI3290410T1/sl unknown
- 2013-04-19 UY UY0001034753A patent/UY34753A/es active IP Right Grant
- 2013-07-29 NO NO13823572A patent/NO2877697T3/no unknown
2014
- 2014-10-07 IL IL235064A patent/IL235064B/en active IP Right Grant
- 2014-10-08 TN TN2014000421A patent/TN2014000421A1/fr unknown
- 2014-10-20 NI NI201400124A patent/NI201400124A/es unknown
- 2014-10-20 CL CL2014002817A patent/CL2014002817A1/es unknown
- 2014-10-20 PH PH12014502351A patent/PH12014502351A1/en unknown
- 2014-10-20 DO DO2014000235A patent/DOP2014000235A/es unknown
- 2014-11-12 US US14/539,318 patent/US9403867B2/en active Active
- 2014-11-18 EC ECIEPI201427739A patent/ECSP14027739A/es unknown
- 2014-11-19 CR CR20140530A patent/CR20140530A/es unknown
- 2014-11-19 ZA ZA2014/08508A patent/ZA201408508B/en unknown
- 2014-11-20 CO CO14255094A patent/CO7131356A2/es unknown
2016
- 2016-04-21 US US15/135,107 patent/US9956261B2/en active Active
- 2016-04-21 US US15/135,147 patent/US9872883B2/en active Active
- 2016-04-21 US US15/135,051 patent/US9981002B2/en active Active
2017
- 2017-03-08 JP JP2017043785A patent/JP6284665B2/ja active Active
2018
- 2018-01-30 JP JP2018013782A patent/JP6616853B2/ja active Active
- 2018-03-05 CY CY20181100270T patent/CY1120276T1/el unknown
- 2018-04-26 US US15/963,284 patent/US10300105B2/en active Active
- 2018-06-28 HK HK18108293.7A patent/HK1248694A1/en unknown
2019
- 2019-04-14 US US16/383,623 patent/US10576122B2/en active Active
2020
- 2020-01-24 US US16/751,836 patent/US10905737B2/en active Active

Also Published As

Publication number	Publication date
CL2014002817A1 (es)	2015-08-14
MX2014012178A (es)	2015-08-05
PT3517532T (pt)	2021-11-08
IL235064B (en)	2019-09-26
US9403867B2 (en)	2016-08-02
EP3517532B1 (fr)	2021-10-13
PE20150084A1 (es)	2015-01-23
PT2838892T (pt)	2018-02-28
CO7131356A2 (es)	2014-12-01
MX354793B (es)	2018-03-21
US20190231843A1 (en)	2019-08-01
CN103857669A (zh)	2014-06-11
JP6109925B2 (ja)	2017-04-05
KR101972998B1 (ko)	2019-04-29
TWI677494B (zh)	2019-11-21
IL235064A0 (en)	2014-12-31
SG10201608488RA (en)	2016-12-29
US20160229889A1 (en)	2016-08-11
US10576122B2 (en)	2020-03-03
DOP2014000235A (es)	2015-01-31
MA37524A1 (fr)	2016-06-30
MD4615C1 (ro)	2019-08-31
US20160237115A1 (en)	2016-08-18
ZA201408508B (en)	2020-01-29
KR102141323B1 (ko)	2020-08-05
MD4615B1 (ro)	2019-01-31
HRP20180316T1 (hr)	2018-04-06
DK3517532T3 (da)	2022-01-03
LT2838892T (lt)	2018-03-12
KR20190044697A (ko)	2019-04-30
PL2838892T3 (pl)	2018-05-30
EP3517532A1 (fr)	2019-07-31
CA3031652A1 (fr)	2013-10-24
CY1120276T1 (el)	2019-07-10
DK2838892T3 (en)	2018-03-12
PL3290410T3 (pl)	2021-01-11
JP2017101082A (ja)	2017-06-08
SG11201406478XA (en)	2014-11-27
JP6284665B2 (ja)	2018-02-28
UY34753A (es)	2013-11-29
JO3353B1 (ar)	2019-03-13
CN110041398A (zh)	2019-07-23
US20140018391A1 (en)	2014-01-16
NZ700833A (en)	2016-01-29
SI2838892T1 (en)	2018-05-31
CR20140530A (es)	2015-03-25
TW201722928A (zh)	2017-07-01
EP3290410A1 (fr)	2018-03-07
MD20140122A2 (ro)	2015-05-31
HUE035697T2 (en)	2018-05-28
UA116207C2 (uk)	2018-02-26
WO2013158874A1 (fr)	2013-10-24
ES2658862T3 (es)	2018-03-12
CN110041304A (zh)	2019-07-23
SI3290410T1 (sl)	2020-11-30
ECSP14027739A (es)	2015-12-31
CN103857669B (zh)	2019-06-28
US20150072934A1 (en)	2015-03-12
AP2014008013A0 (en)	2014-10-31
TW201348224A (zh)	2013-12-01
PH12014502351B1 (en)	2015-01-12
US10300105B2 (en)	2019-05-28
AU2013249197A1 (en)	2014-10-30
NI201400124A (es)	2015-09-21
EP3290410B1 (fr)	2020-07-01
CA2869893C (fr)	2019-03-05
JP2015514779A (ja)	2015-05-21
PH12014502351A1 (en)	2015-01-12
CA2869893A1 (fr)	2013-10-24
TWI589572B (zh)	2017-07-01
BR112014025972A8 (pt)	2021-06-22
JP6616853B2 (ja)	2019-12-04
EP2838892B1 (fr)	2017-12-06
HK1248694A1 (en)	2018-10-19
MA37524B1 (fr)	2017-04-28
US20160235804A1 (en)	2016-08-18
JP2018076375A (ja)	2018-05-17
NO2877697T3 (fr)	2018-10-13
US10905737B2 (en)	2021-02-02
EA201401151A1 (ru)	2015-06-30
MY170068A (en)	2019-07-03
ES2820354T3 (es)	2021-04-20
EP2838892A1 (fr)	2015-02-25
US20200276259A1 (en)	2020-09-03
ME02966B (fr)	2018-07-20
US9956261B2 (en)	2018-05-01
US9981002B2 (en)	2018-05-29
HUE050865T2 (hu)	2021-01-28
RS56869B1 (sr)	2018-04-30
US20190000914A1 (en)	2019-01-03
KR20150013115A (ko)	2015-02-04
EA031581B1 (ru)	2019-01-31
HK1202863A1 (en)	2015-10-09
US9872883B2 (en)	2018-01-23
GEP20186902B (en)	2018-10-25
CA3031652C (fr)	2020-10-27
AR090725A1 (es)	2014-12-03
BR112014025972A2 (pt)	2017-06-27
AU2013249197B2 (en)	2017-04-06

Publication	Publication Date	Title
PH12013501821A1 (en)	2019-06-03	Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
MX2015006324A (es)	2015-09-07	Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
PH12014501595A1 (en)	2014-10-08	Substituted annulated pyrimidines and triazines, and use thereof
MX2021011906A (es)	2021-10-26	Composiciones de liberacion retardada de linaclotida.
IN2014DN10386A (fr)	2015-08-14
MX2016003823A (es)	2016-08-01	Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
UA111186C2 (uk)	2016-04-11	Способи та композиції для одержання норибогаїну з воакангіну
PL2922893T3 (pl)	2017-08-31	Kompozycje utwardzane wilgocią, sposób ich wytwarzania i ich zastosowania
MX2014010433A (es)	2015-04-13	Nueva forma cristalina de sulfato de sitagliptina.
EA032271B9 (ru)	2019-08-30	Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2016008369A (es)	2016-12-15	Composicion farmaceutica que incluye palonosetron.
WO2013164839A8 (fr)	2014-01-09	Forme amorphe d'apixaban, son procédé de préparation et compositions de celle-ci
PH12014502351B1 (en)	2015-01-12	Methods of producing anamorelin hydrochloride having controlled chloride content
IN2013MU03641A (fr)	2015-07-31
MX2015000179A (es)	2016-02-16	Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2015016603A (es)	2016-07-28	Composiciones de corticosteroides.
MX367773B (es)	2019-09-05	Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX2014006201A (es)	2014-12-05	Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
GEP201706614B (en)	2017-02-10	Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
IN2013MU02777A (fr)	2015-07-03
MY168958A (en)	2019-01-28	Intermediates and processes for preparing compounds
MX2012014969A (es)	2013-08-26	Composiciones farmaceuticas estables de amlodipina con telmisartan.